Imagion Biosystems is pleased to provide an update on its progress and plans for manufacturing of its proprietary nanoparticle formulation in advance of the first in human study currently planned for mid-2020.
Read the update.
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
September 9, 2025
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer